| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: NWBT |
| Security Type |
Common Stock |
| Lead Underwriter |
CE Unterberg Towbin |
| Days In Registration |
123 |
| Date Filed |
13-Aug-2001 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2008) |
| Industry |
Manufacturing |
| Business Description |
Northwest Biotherapeutics Inc, based in United States, is a development-stage biotechnology company focused on discovering, developing, and commercializing immunotherapy products that generate and enhance immune system responses to effectively treat cancer. Its approach in developing cancer therapies utilizes its capability in the biology of dendritic cells (DC), which are a type of white blood cells that activate the immune system. |
| Revenue |
$0.1M |
| Net Income |
-$10.9M |
| Shares Outstanding (post-offering) |
16.35M |
| Chairman, President & CEO |
Daniel O. Wilds |
| Number of Employees |
51 |
|
| Original Filing Information |
| US |
| Shares Filed |
- |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
- |
| · As a Percent |
- |
| Overallotment Shares Filed |
600.0K |
| File Amount |
- |
| File Price Range |
$11.00 - $9.00 |
| File Mid Price |
$10.00 |
Current Filing Information
(Amended 14-Dec-2001) |
|
US |
|
Shares Filed |
4.0M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
4.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$22.0M |
| · % Change from Original |
|
| File Price Range |
$6.00 - $5.00 |
| File Mid Price |
$5.50 |
|
